Entia Biosciences, Inc.
ERGO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.66K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $33,661.00 |
|---|---|
| Enterprise Value | $1.00 Million |
| Earnings per Share | $-0.05 |
| Beta | 3.27 |
| Outstanding Shares | 28,146,124 |
Return
| Return on Equity | 74.88% |
|---|---|
| Return on Assets | -335.35% |
| Return on Invested Capital | 79.03% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | -0.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 3.78 |
| Enterprise Value to EBIT | -0.76 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.04 |
| Debt to Equity | -0.53 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Entia Biosciences, Inc.
6 employees
CEO: Timothy A. Timmins
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound...